Karo Pharma (Cancer Project KB9520)

Karo Pharma (Cancer Project KB9520) Overview

Status Acquired/​Merged
Latest Deal Type Asset Purch.
Financing Rounds 1

Karo Pharma (Cancer Project KB9520) General Information

Description

KB9520 estrogen receptor cancer drug developed for cancer treatment. The asset provides various type of cancer treatment.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Primary Office
  • Nybrokajen 7
  • Stockholm
  • Sweden
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Karo Pharma (Cancer Project KB9520) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Karo Pharma (Cancer Project KB9520)‘s full profile, request access.

Request a free trial

Karo Pharma (Cancer Project KB9520) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Karo Pharma (Cancer Project KB9520)‘s full profile, request access.

Request a free trial